Andrew Vickers, PhD

Attending Research Methodologist

Andrew Vickers, PhD

Attending Research Methodologist
Dr. Andrew Vickers

Office Phone



Oxford University, UK

Current Research Interests

Dr. Vickers has conducted extensive methodologic and empirical research in clinical trials, patient-reported outcomes, prediction modelling and molecular markers. He developed novel, streamlined, trial methodologies that have allowed large randomized trials to be conducted at very low cost; spearheaded methods for adapting patient-reported outcomes instruments into clinical care; created decision curve analysis, now a routine statistical method for the evaluation of prediction models; was the statistician behind the 4Kscore, the first laboratory test to give a predicted probability of disease, and which is in wide use in urologic practice to inform decisions about prostate biopsy. A particular focus of Dr. Vickers’ work is the detection and initial treatment of prostate cancer, having published on the prognostic value of baseline PSA, the surgical learning curve, PSA velocity, MRI-targeting, Gleason grading and active surveillance. Dr Vickers has a strong interest in teaching statistics. He is course leader for the MSK biostatistics course and is author of the introductory textbook “What is a p-value anyway?”. Dr. Vickers spearheads a number of innovative informatics initiatives throughout MSK, including patient-reported outcomes, part of his work as Co-Director of the PRO-CEL Core Facility, and the Amplio surgical quality assurance system.


Selected peer-reviewed publications:

  1. Touijer KA, Sjoberg DD, Benfante N, Laudone VP, Ehdaie B, Eastham JA, Scardino PT, Vickers A. Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol. 2021 Aug;4(4):532-539.
  2. Vickers AJ, Tin AL, Singh K, Dunn RL, Mulhall J. Updating the International Index of Erectile Function: Evaluation of a Large Clinical Data Set. J Sex Med. 2020 Jan;17(1):126-132.
  3. Vertosick EA, Häggström C, Sjoberg DD, Hallmans G, Johansson R, Vickers AJ, Stattin P, Lilja H. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. J Urol. 2020 Aug;204(2):281-288.
  4. Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Lilja H. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013 Apr 15;346:f2023. 
  5. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006 Nov-Dec;26(6):565-74.​​​​​​​

View a full listing of Andrew Vickers’ journal articles.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Andrew Vickers discloses the following relationships and financial interests:

  • Arctic Partners
    Intellectual Property Rights
  • European Association of Urology
    Professional Services and Activities
  • Gryphon
    Professional Services and Activities (Uncompensated)
  • OPKO Health, Inc.
  • Steba Biotechnology
    Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures